Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Buy rating on Travere Therapeutics and increased the price target from $18 to $23, indicating a positive outlook for the company's stock.
September 10, 2024 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has maintained a Buy rating on Travere Therapeutics and increased the price target from $18 to $23, suggesting a positive outlook for the stock.
The increase in the price target from $18 to $23 by Canaccord Genuity reflects a positive sentiment towards Travere Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100